IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

Prevention of liver fibrosis and steatosis progression among heavy drinkers with and without
HIV after 30-day drinking-reduction program
Seungjun Ahn ^{1,3*} , Veronica Richards ^{2,3,7} , Emmanuel Thomas ⁴ , Dushyantha Jayaweera ⁴ , Varan
Govind ⁶ , Zhigang Li ^{1,3} , Ronald A. Cohen ^{3,5} , Robert L. Cook ^{2,3} .
¹ Department of Biostatistics, University of Florida, Gainesville, FL 32611, U.S.A.
² Department of Epidemiology, University of Florida, Gainesville, FL 32611, U.S.A.
³ Southern HIV and Alcohol Research Consortium, Emerging Pathogens Institute, Gainesville,
FL 32610, U.S.A.
⁴ Schiff Center for Liver Disease, University of Miami Miller School of Medicine, Miami, FL
33136, U.S.A.
⁵ Department of Clinical and Health Psychology, University of Florida, Gainesville, FL 32610,
U.S.A.
⁶ Department of Radiology, University of Miami Miller School of Medicine, Miami, FL 33136,
U.S.A.
⁷ Edna Bennett Pierce Prevention Research Center, Pennsylvania State University, University
Park, PA 16802, U.S.A.
NOTE: This preprint reports new research that has not been cartified by peer review and should not be used to guide clinical practice.
*Corresponding Author:
<i>E-mail</i> : <u>sahn1@ufl.edu</u> (S.A.)

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

32 Abstract

33	Background: This is the first attempt to assess changes in liver abnormalities before and after
34	contingency management (CM) to reduce heavy drinking beyond 30-days of follow-up.
35	Objective: The main objective was to determine whether liver fibrosis and steatosis, measured
36	using FibroScan, change significantly between baseline, 30-days, and 90-days among older
37	adults who drink heavily at baseline, enrolled in the CM intervention for alcohol reduction. The
38	secondary aim of the study was to assess whether the changes in liver outcome measures differ
39	across alcohol consumption categories.
40	Methods: A prospective study (ClinicalTrials.gov registry: NCT03353701) of 46 older adults
41	(63% male, 76.1% Black, mean age = 56.4) with heavy drinking at the baseline, living with or
42	without HIV infection was evaluated. A linear mixed-effects model was used to analyze the
43	FibroScan Transient Elastography (TE for fibrosis) and Controlled Attenuation Parameter (CAP
44	for steatosis).
45	Results: There were no significant changes in liver fibrosis and steatosis measures after 90-days
46	of drinking abstinence among heavy drinkers with or without stratified TE or CAP values at
47	baseline.
48	Conclusions: CM for drinking reduction may not be effective at least short-term prospective in
49	preventing liver fibrosis and steatosis progression for subjects without severe liver disease at
50	baseline.
51	
52	
53	
54	
55	
56	
57	
58	Abbreviations: CM, contingency management; TE, Transient elastography; CAP, Controlled
59	attenuation parameter; HIV, Human immunodeficiency virus; PLWH, Persons living with HIV;
60	NAFLD, Non-alcoholic fatty liver disease; ALT, aminotransferase; GGT, gamma-glutamyl
61	transferase; ALD, Alcoholic-related liver disease; FIB-4, Fibrosis-4; AST, Aspartate
62	aminotransferase; TLFB, Alcohol timeline followback; HCV, Hepatitis C

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

63 Introduction

64 Alcohol use is the third leading preventable cause of death in the United States [1, 2]. Heavier alcohol use has consistently been reported to be associated with increased risk for numerous 65 chronic diseases and conditions, such as liver diseases [3, 4, 5, 6]. With respect to liver diseases, 66 67 alcohol-attributable mortality from liver cirrhosis, an advanced stage of liver fibrosis, accounted 68 for 47.9 percent of all liver cirrhosis deaths worldwide (493,300 deaths) [3]. Liver steatosis (fatty 69 liver) is detected in 90% of people with heavy alcohol consumption [5, 7]. Although liver 70 steatosis is usually asymptomatic [5], it can progress to liver inflammation and liver cirrhosis [8]. 71 Though the relationship between heavy alcohol consumption and liver diseases are an 72 established public health concern, it is unclear how reducing or cessating from alcohol 73 consumption is associated with prevention of liver outcomes progression, warranting further 74 investigation. 75 Alcohol use is prevalent among persons living with HIV (PLWH) [9, 10], which is also 76 associated with incidence of liver disease [9]. Liver disease is one of the leading causes of death 77 78 among PLWH [10]. A recent cohort study [11] noted that the prevalence of liver diseases among 79 PLWH were 10 times higher compared with HIV-negative counterparts. A systematic review 80 [12] reported that the prevalence of non-alcoholic fatty liver disease (NAFLD) and fibrosis were 81 35% and 22% in PLWH, respectively. Moreover, HIV is associated with steatosis [13] and 82 chronic systemic inflammation, which may place PLWH at higher risk for developing liver

84

83

disease [14].

85 A review article [15] highlighted the need of intervention for drinking reduction and for better understanding of HIV-related health outcomes at individual and policy levels. Contingency 86 87 management (CM) is one drinking intervention that has been effective for alcohol reduction [16, 88 17]. CM involves providing financial or other incentives for meeting a treatment goal or, a 89 negative consequence if the individual is unable to meet this goal. However, there is limited 90 published information about how short-term alcohol interventions, such as CM, may impact liver 91 disease, especially in PLWH and in the persons without severe liver disease at baseline. Among 92 two populations of "healthy" individuals who drank moderately-to-heavily, short-term 93 abstinence (one month) from alcohol resulted in significantly reduced serum alanine

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

94 aminotransferase (ALT) and gamma-glutamyl transferase (GGT), both indicating improvement

95 in liver function [18, 19]. The study outcomes for these two studies were assessed only at 30-

96 days, so it is unclear if these benefits persisted after 30-days. Further, it is unclear whether any

97 benefits of alcohol reduction extended to prevent liver fibrosis and steatosis progression, key

98 manifestations of both alcoholic-related liver disease (ALD) and NAFLD.

99

100 The primary objective of this study was to determine whether liver fibrosis and steatosis,

101 measured using FibroScan, change significantly with alcohol reduction from a CM intervention,

102 over three time periods (baseline, 30-days, and 90-days) among older adults who drink heavily

103 with or without stratified liver fibrosis and steatosis values at baseline. In the current study, the

104 fibrosis-4 (FIB-4) index [20] was analyzed as an additional liver outcome measure. We

105 hypothesized that the patterns of change in liver outcome measures would differ in alcohol

106 consumption categories (*i.e. quit/reduced drinking vs. continued heavy drinking*) during the

107 course of study, observed by an interaction effect between alcohol intake and time from an

108 analysis. This study would increase knowledge and empirical evidence on the prevention of

109 progression in liver abnormalities, fibrosis and steatosis before and after the initiation of a

110 drinking abstinence program.

111

112 Materials and Methods

113 Study Participants

114 This prospective study included older adults (aged 50 to 75 years) with heavy drinking (≥ 14 115 drinks/week for women, ≥21 drinks/week for men) at the baseline, living with or without HIV 116 infection, and were enrolled in a clinical trial of drinking-reduction from 12/11/2017 to 11/16/2021. A description of the methods of drinking-reduction program, "30-Day Challenge 117 118 Study," is available in ClinicalTrials.gov registry and is shown in Fig 1. The trial was registered 119 under ClinicalTrials.gov with registry date and number (11/27/2017) (NCT03353701) respectively. In brief, the "30-Day Challenge Study" used CM with financial incentives to 120 121 measure the impact of changes in alcohol consumption on changes in neurocognitive disorders, liver fibrosis, and other HIV-related comorbidities. All procedures in the "30-Day Challenge 122 123 Study" were approved by the central Institutional Review Board at University of Miami (Study

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

5

124 Number: 20170396). All study participants provided informed consent prior to participation. All

- 125 methods were carried out in accordance with relevant guidelines and regulations.
- 126

127 Fig 1. Timeline of the 30-Day Challenge Study. The data used in this analysis come from the

128 baseline, 30-day, and 90-day follow-up visits, with measures included listed below each

- 129 timepoint. The contingency management (CM) period began at Baseline and ended at the 30-day
- 130 follow-up.
- 131
- 132 This study analyzed data from the baseline, 30-day follow-up (post CM), and 90-day follow-up
- 133 visits. At the time of data retrieval (12/07/2021), the dataset included 56 participants, but 10 were
- excluded from the analysis due to missing baseline (n = 1), or missing both 30-days and 90-days
- follow-up data on alcohol consumption (n = 8), or AST level (n = 1). In summary, data were
- 136 included from 46 participants with complete information on alcohol intake and liver outcome

137 measures at baseline and at least one follow-up visit.

138

139 **Outcome Measures**

The outcome variables included the changes from baseline values on liver fibrosis measured by transient elastography (TE), and steatosis measured by controlled attenuation parameter (CAP), respectively. These quantitative measures were obtained using a FibroScan (Echosens, Paris, France) from baseline, 30-days, and 90-days. Additionally, the fibrosis-4 (FIB-4) index [20], a validated noninvasive test alternative to liver biopsy, was considered to further investigate the trend in liver fibrosis, calculated as,

146

$$FIB-4 = \frac{Age \times AST}{Platelet \ Count \times \sqrt{ALT}}$$

where AST = aspartate aminotransferase and ALT = alanine aminotransferase. Hence, the
changes from baseline value on FIB-4 was also considered as an outcome variable.

149

150 Main Predictor

151 Although abstinence is often regarded as the primary endpoint in alcohol use disorder treatment,

the prior studies [21, 22] have shown that reduced alcohol consumption at any level has also

been linked to improved health outcomes. Thus, we decided to examine alcohol consumption as

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

a dichotomous variable rather than a 3-level categorical variable. Alcohol intake categories were
derived from the Alcohol Timeline Followback (TLFB) [23] data in the previous 30-days. *Heavy drinking* was defined as consuming more than 7 drinks per week for females and more than 14
drinks per week for males, based on the National Institute on Alcohol Abuse and Alcoholism
(NIAAA) guideline [24]; *reduced drinking* was definined as drinking level that did not qualify
as heavy drinking; 3) *quit drinking* if a participant did not drink during 30 days. In this study,
reduced and quit drinking categories are combined for the analysis.

161

162 **Covariates**

163 HIV diagnosis (negative or positive), body mass index (BMI), sex at birth (female or male), age

164 in continuous scale, and hepatitis C (HCV) were included as covariates in later multivariable

analysis. HCV antibody test was conducted at baseline and classified as positive or negative.

166 HCV was included as a covariate, as earlier research showed that the alcohol consumption is

related to the transmission of both HIV and HCV [25]. BMI was broken down into three

168 categories: underweight or normal (BMI < 25.0), overweight ($25.0 \le BMI < 30.0$), and obese

169 (BMI \ge 30) based on the Centers for Disease Control and Prevention classification of

170 overweight and obesity guideline [26]. Previous studies have shown that obesity is the important

171 risk factor for NAFLD [8, 27].

172

173 Statistical Methods

A linear mixed-effects model with random intercept was used to determine the changes in FibroScan (TE and CAP), and FIB-4 score while accounting for within-subject correlations. An unstructured covariance matrix was used. The change in log-transformed values of TE and FIB-4 were used as outcomes after examining residual diagnostics and standard model assumptions (normality). However, the results were back-transformed and presented in their original scales for the purpose of simplicity. As a subgroup analysis, we performed similar analyses among participants with abnormal baseline values of TE (\geq 7 kPa) and CAP (\geq 238 dB/m) [28, 29].

We firstly fitted the marginal models (unadjusted models) for each predictor variable to identify covariates that are marginally associated with each liver outcome variable at p < 0.10 (forward selection). Subsequently, multivariable models (adjusted models) included time, categorical

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

185	alcohol intake, interaction term with alcohol intake and time, and the covariates that were
186	significantly associated with each liver outcome variables from unadjusted models. Lastly,
187	backward elimination was applied to identify covariates that are associated with liver outcome
188	variables in adjusted models, including only covariates with $p < 0.05$. Time was treated as a
189	continuous variable.
190	
191	Demographic characteristics were presented as mean and standard deviation (SD) for continuous
192	variables and frequencies with percentages for categorical variables. Results were considered

193 statistically significant when p < 0.05. All analyses were conducted using SAS version 9.4 (SAS

194 Institute, Inc., Cary, NC).

195

196 Sample Size Considerations

197 The sample size (n = 46) was based on availability of data during the time span of the database

retrieval. A sample size of 46 yielded 85.7% statistical power to detect a large effect size

199 (Cohen's f = 0.5), determined by repeated measures ANOVA with a significance level of 0.05. A

200 statistical power calculation was performed in R version 4.0.2 (R Foundation for Statistical

201 Computing, Vienna, Austria).

202

203 **Results**

204 **Demographic and Clinical Characteristics**

205 The baseline characteristics are summarized in Table 1. The final data included 46 participants.

206 Overall, the mean age of study participants was 56.4 years (SD = 4.7 years). A majority of

207 participants were diagnosed with HIV (n = 28; 60.9%) and were either overweight (n = 15;

208 32.6%) or obese (n = 13; 28.3%). Most participants were Black (n = 35; 76.1%) and male sex (n

209 = 29; 63.0%). With 9 and 3 missing values, a majority of participants smoked cigarettes (n = 30;

- 210 81.1%) and were HCV negative (n = 38; 88.4%) at the time of enrollment in the 30-Day
- 211 Challenge Study.
- Approximately 20% of participants had mild (n = 4) or severe (n = 5) fibrosis and almost half (n
- 213 = 21; 45.6%) had steatosis. The majority of participants did not have fibrosis (n = 27; 58.7%)
- based on FIB-4 index.

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

8

216 **Table 1. Baseline characteristics of study participants in the study.**

Charactertistics	Total $(n = 46)$
Mean Age (SD) in years	56.4 (4.7)
Mean alcohol start age (SD) in years	18.9 (5.7)
Sex at birth n (%)	
Female	17 (37.0)
Male	29 (63.0)
Race <i>n</i> (%)	
Black/African-American	35 (76.1)
White	9 (19.6)
Multiracial	2 (4.4)
Drinking behavior <i>n</i> (%)	
> 14 drinks/week	46 (100.0)
> 28 drinks/week	38 (82.6)
Steatosis grade ^a n (%)	
No steatosis (S0)	25 (54.4)
Mild steatosis (S1)	3 (6.5)
Moderate steatosis (S2)	7 (15.2)
Severe steatosis (S3)	11 (23.9)
Fibrosis stage ^b n (%)	
No or mild scarring	37 (80.4)
Mild fibrosis	4 (8.7)
Severe fibrosis	5 (10.9)
FIB-4 categories ^c <i>n</i> (%)	
Absence of fibrosis	27 (58.7)
Inconclusive	16 (34.8)
Severe fibrosis	3 (6.5)
HIV diagnosis <i>n</i> (%)	
Negative	18 (39.1)
Positive	28 (60.9)
BMI ^d <i>n</i> (%)	
Underweight/Normal	18 (39.1)
Overweight	15 (32.6)
Obese	13 (28.3)
Hepatitis $C^* n$ (%)	
Negative (< 0.8)	38 (88.4)
Positive (> 0.9)	5 (11.6)

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

Current smoking status ^{**} n (%)		
	No	7 (18.9)
	Yes	30 (81.1)

- 217 Data reported as mean (SD) for continuous variables and frequencies with percentages for
- 218 categorical variables; SD = standard deviation.
- 219 Percentages may not add up to 100% due to rounding.
- 220 FIB-4 = Fibrosis-4 index; SD = standard deviation.
- 221 a S0: CAP < 238 dB/M; S1: 238 \leq CAP < 260 dB/M; S2: 260 \leq CAP < 293 dB/M; S3: CAP \geq 293 dB/M [30]
- ²²³ ^b No or mild scarring: $2 \le TE < 7.1$ kPa; mild fibrosis: $7.1 \le TE < 9.5$ kPa; severe fibrosis: $TE \ge$ 224 9.5 kPa [30].
- ²²⁵ ^c Absence of fibrosis: FIB-4 < 1.45; inconclusive: $1.45 \le$ FIB-4 \le 3.25; severe fibrosis: FIB-4 > 3.25 [20].
- ^d Underweight/normal: BMI < 25.0; overweight: $25.0 \le BMI < 30.0$; obese: BMI ≥ 30 .
- 228 * 3 missing values; ** 9 missing values.
- 229

230 Unadjusted Models for Screening Covariates (Forward Selection of

231 Model Covariates)

- In the unadjusted model using the entire sample, age (type III p = 0.047) and sex (type III p =
- 233 0.019) were marginally associated with the the change in CAP. None of the covariates were
- significantly associated with changes in TE or FIB-4.
- 235
- In the marginal analysis using subsamples with abnormal baseline TE, HCV (type III p = 0.010)
- and sex (type III p = 0.015) were significantly associated with change in TE. There were
- marginal associations between FIB-4 and HCV (type III p = 0.080). None of covariates were
- significantly associated with change in CAP in this subsample.
- 240 With subsamples of abnormal baseline CAP, age (type III p = 0.009), HIV (type III p = 0.052),
- and BMI (type III p = 0.012) were significantly associated with change in CAP. There was
- significant marginal association between FIB-4 and BMI (type III p = 0.009). Lastly, TE did not
- 243 have marginal association with any covariates.
- 244
- 245 Subsequently, marginally significant covariates were included in the initial multivariable model
- 246 for the backward elimination.
- 247
- Adjusted Models for Liver Outcomes Using Entire Samples (n = 46)

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

10

249 The results presented in Table 2 indicate that there was no significant change in any of liver

250 outcomes for every one-day increase in time regardless of the level of alcohol intake (interaction

terms). Males had significantly smaller changes in levels of CAP ($\hat{\beta} = -22.90$; 95% CI of $\hat{\beta}$: -

41.49, -4.301; p = 0.017), when compared to females. Older age was associated with greater

253 changes in levels of CAP ($\hat{\beta} = 2.489$; 95% CI of $\hat{\beta}$: 0.538, 4.441; p = 0.014).

254

Table 2. Changes in liver outcomes associated with changes in alcohol consumption at 30 and 90 days among 46 adults participating in a contingency management study.

		Outcomes									
		Change in TE			Change in CAP			Change in FIB-4			
Variables	$\exp{(\hat{\beta})}$	95% CI of exp $(\hat{\beta})$	p-value	β	95% CI of $\hat{\beta}$	p-value	$\exp{(\hat{\beta})}$	95% CI of exp $(\hat{\beta})$	p-value		
Main Predictors											
Time	1.000	0.997, 1.002	0.930	0.022	-0.321, 0.366	0.895	1.000	0.997, 1.003	0.913		
Alcohol intake											
Continued heavy drinking	‡	* *	* *	*	++	*	‡	++	‡		
Quit/Reduced drinking	1.080	0.849, 1.372	0.521	-22.96	-63.31, 17.40	0.255	1.053	0.795, 1.393	0.712		
Time × <i>I</i> (Alcohol intake = Quit/Reduced drinking)	0.999	0.995, 1.002	0.485	0.343	-0.244, 0.931	0.243	0.999	0.995, 1.004	0.810		
Baseline liver measure ^a	0.786	0.633, 0.977	0.031*	-0.246	-0.420, -0.072	0.007^{*}	0.674	0.502, 0.905	0.010^{*}		
Covariates ^b											
Age				2.489	0.538, 4.441	0.014*					
Sex at birth											
Female				*	**	* *					
Male				-22.90	-41.49, -4.301	0.017*					

257 All mixed-effects models included linear function of time, categorical alcohol intake, and an

interaction term with categorical alcohol intake and time. An unstructured covariance structurewas used.

260 The coefficient estimates for TE and FIB-4 were back-transformed, that is, exponent of the

261 coefficient estimates.

^a This is to adjust the outcome at baseline. For example, CAP at baseline is used as a predictor
 for the fitted model for change in CAP as an outcome variable.

^b In these models, age in years, HIV diagnosis, BMI categories, hepatitis C diagnosis, and sex

were firstly considered as potential confounders and to be selected from unadjusted models at the

0.1 significance level. Selected covariates were then remained after backward elimination at the0.05 significance level.

268 TE = fibrosis measured using FibroScan; CAP = steatosis measured using FibroScan; FIB-4 =

269 Fibrosis-4 index; $\hat{\beta}$ = coefficient estimates; CI = confidence interval

^{*} A p-value < 0.05 was considered statistically significant, unless otherwise noted.

271 ‡ Reference group for comparisons.272

273

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

11

275 Adjusted Models for Liver Outcomes with Abnormal Baseline TE

276 Samples (*n* = 9)

- 277 The interaction terms of the mixed-effects model results using samples with abnormal baseline
- 278 TE (Table 3) highlights that there were no significant changes in liver outcome measures with
- 279 varying alcohol intake categories for every one-day increase in time. Of them, the greater change
- 280 (increase) in FIB-4 from baseline for every one-day increase in time was observed for those who
- 281 quit or reduced drinking $(\exp(\hat{\beta}) = 1.010; 95\%$ CI of $\exp(\hat{\beta}): 0.999, 1.021; p = 0.067)$, when
- compared with continued heavy drinking, albeit not statistically significant. This implies that
- 283 34.8% higher level of FIB-4 in quit or reduced drinking versus continued heavy drinking after 30
- 284 days, calculated by $\left[\exp(30 * \hat{\beta})\right] * 100\%$.
- 285
- 286 Sex (p = 0.229) and HCV (p = 0.086) were excluded from the final adjusted model after the

backward elimination for TE. HCV was remained significant in the model for FIB-4 (p = 0.006)

after the backward elimination.

289

290Table 3. Changes in liver outcomes associated with changes in alcohol consumption at 30291and 90 days among 9 adults with abnormal baseline TE (TE \geq 7) participating in a292contingency management study.

		Outcomes								
		Change in TE			Change in CAP		Change in FIB-4			
Variables	$\exp(\hat{\beta})$	95% CI of exp $(\hat{\beta})$	p- value	β	95% CI of $\hat{\beta}$	p- value	$\exp{(\hat{\beta})}$	95% CI of exp $(\hat{\beta})$	p-value	
Main Predictors										
Time	1.001	0.991, 1.012	0.741	-0.194	-1.396, 1.007	0.677	0.994	0.986, 1.001	0.072	
Alcohol intake										
Continued heavy drinking	‡	*	‡	‡	‡	‡	‡	*	‡	
Quit/Reduced drinking	1.747	0.630, 4.844	0.203	-29.60	-147.6, 88.37	0.524	0.400	0.179, 0.892	0.034*	
Time × <i>I</i> (Alcohol intake = Quit/Reduced drinking)	0.994	0.979, 1.010	0.383	1.055	-0.733, 2.843	0.177	1.010	0.999, 1.021	0.067	
Baseline liver measure ^a	1.105	0.590, 2.072	0.681	-0.252	-0.925, 0.420	0.356	0.327	0.193, 0.553	0.004^{*}	
Covariates ^b										
Hepatitis C										
Negative							‡	* +	÷	
Positive							2.727	1.602, 4.641	0.006^{*}	

All mixed-effects models included linear function of time, categorical alcohol intake, and an

interaction term with categorical alcohol intake and time. An unstructured covariance structurewas used.

296 The coefficient estimates for TE and FIB-4 were back-transformed, that is, exponent of the

297 coefficient estimates.

^a This is to adjust the outcome at baseline. For example, CAP at baseline is used as a predictor

299 for the fitted model for change in CAP as an outcome variable.

^b In these models, age in years, HIV diagnosis, BMI categories, hepatitis C diagnosis, and sex

301 were firstly considered as potential confounders and to be selected from unadjusted models at the

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

- 302 0.1 significance level. Selected covariate was then remained after backward elimination at the
- 303 0.05 significance level.

304 TE = fibrosis measured using FibroScan; CAP = steatosis measured using FibroScan; FIB-4 = 305 Fibrosis-4 index; $\hat{\beta}$ = coefficient estimates; CI = confidence interval.

- ^{*} A p-value < 0.05 was considered statistically significant, unless otherwise noted.
- 307 ‡ Reference group for comparisons.
- 308

309 Adjusted Models for Liver Outcomes with Abnormal Baseline CAP

310 Samples (*n* = 21)

- 311 In the mixed-effects model using samples with abnormal baseline CAP (Table 4), there was no
- 312 statistically significant interaction effect of time and alcohol intake categories on changes in liver
- 313 outcome measures. Although it was not statistically significant, it is noteworthy that the greater
- 314 change (increase) in CAP from baseline for every one-day increase in time was observed for
- 315 those who quit or reduced drinking ($\hat{\beta} = 0.315$; 95% CI of $\hat{\beta}$: -0.588, 1.218; p = 0.465), when
- 316 compared with continued heavy drinking.
- 317
- 318 BMI remained in the final adjusted model for CAP and FIB-4 after backward elimination. Obese
- 319 $(\exp(\hat{\beta}) = 1.285; 95\% \text{ CI of } \exp(\hat{\beta}): 1.079, 1.531; p = 0.009)$ participants had 28.5% significantly
- 320 higher level of FIB-4 from baseline, comparing with those who were either underweight or
- normal. Lastly, HIV (p = 0.174) and age (p = 0.066) were excluded from the final adjusted
- 322 models for CAP after the backward elimination.

Table 4. Changes in liver outcomes associated with changes in alcohol consumption at 30 and 90 days among 21 adults with abnormal baseline CAP (CAP \ge 238) participating in a contingency management study.

		Outcomes								
		Change in TE			Change in CAP			Change in FIB-4		
Variables	$\exp{(\hat{\beta})}$	95% CI of exp $(\hat{\beta})$	p-value	β	95% CI of $\hat{\beta}$	p-value	$\exp{(\hat{\beta})}$	95% CI of exp $(\hat{\beta})$	p-value	
Main Predictors										
Time	0.998	0.992, 1.003	0.330	0.037	-0.365, 0.438	0.846	1.001	0.996, 1.007	0.549	
Alcohol intake										
Continued heavy drinking	‡	++	÷	‡ ‡	* +	‡	* *	* + +	‡	
Quit/Reduced drinking	0.855	0.546, 1.338	0.468	-16.28	-78.96, 46.41	0.584	1.047	0.754, 1.453	0.767	
Time × <i>I</i> (Alcohol intake = Quit/Reduced drinking)	1.001	0.994, 1.007	0.815	0.315	-0.588, 1.218	0.465	0.999	0.993, 1.005	0.699	
Baseline liver measure ^a	0.830	0.653, 1.055	0.118	-0.473	-0.907, -0.038	0.035*	0.869	0.727, 1.040	0.115	
Covariates ^b										
BMI										

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

13

Underweight/Normal		÷.	* *	‡ ‡	* *	* *	‡
Overweight		25.72	-0.735, 52.17	0.056	1.095	0.874, 1.371	0.399
Obese		51.15	17.13, 85.18	0.006^{\dagger}	1.285	1.079, 1.531	0.009^{\dagger}

All mixed-effects models included linear function of time, categorical alcohol intake, and an interaction
 term with categorical alcohol intake and time. An unstructured covariance structure was used.
 The coefficient estimates for TE and FIB-4 were back-transformed, that is, exponent of the coefficient
 estimates.

^a This is to adjust the outcome at baseline. For example, CAP at baseline is used as a predictor for the
 fitted model for change in CAP as an outcome variable.

^b In these models, age in years, HIV diagnosis, BMI categories, hepatitis C diagnosis, and sex were firstly
 considered as potential confounders and to be selected from unadjusted models at the 0.1 significance

- level. Selected covariates were then remained after backward elimination at the 0.05 significance level.
- 335 TE = fibrosis measured using FibroScan; CAP = steatosis measured using FibroScan; FIB-4 = Fibrosis-4 336 index; $\hat{\beta}$ = coefficient estimates; CI = confidence interval.

^{*} A p-value < 0.05 was considered statistically significant, unless otherwise noted.

[†] A Bonferroni-corrected p-value of 0.0167 was considered statistically significant results for BMI.

339 ‡ Reference group for comparison

340

342

341 **Discussion**

343 before and after CM to reduce heavy drinking beyond 30-days of follow-up. To date, no studies

To our knowledge, this study is the first of its kind in the literature to evaluate liver abnormalities

have examined whether reduction in drinking will have an effect in a population of persons

345 without severe liver disease to start with, but who are at high risk for progression. In this study,

346 the interaction term obtained in an analysis showed that there were no significant changes in

347 liver abnormalities after 90-days of drinking abstinence or reduction among heavy drinkers with

348 or without stratified TE and CAP values at baseline. This suggests that CM for drinking

349 reduction may not be effective at least short-term prospective in improving liver fibrosis and

350 steatosis for subjects with or without abnormal levels of TE or CAP. It is not surprising to see

that the behavioral intervention has not always been successful in improving health outcomes. A

352 recent study has shown that the dietary behavioral intervention to increase vegetable intake did

not significantly reduce cancer progression in men with early-stage prostate cancer [31]. In

addition, results of the meta-analysis suggested that a brief intervention on alcohol consumption

did not substantially reduce cigarette smoking in terms of frequency of smoking and likelihood

of smoking cessation [32]. Although we did not see an improvement in our study, it is

357 noteworthy that there was no significant change in liver abnormalities over time. Therefore, the

358 liver disease did not progress further stages. It remains a question whether our intervention is

359 what prevented the disease progression.

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

361 Additional findings of this study have identified a number of covariates that are significantly 362 associated with liver outcome measures. Participants with HCV infection had substantially 363 higher levels of FIB-4 with stratified TE values at baseline, when compared with those without 364 HCV infection. It is important to note that none of the participants had advanced alcoholic liver disease or acute alcoholic hepatitis at the time of study enrollment. Moreover, the majority of the 365 366 study participants were recruited from an HIV clinic, not a liver clinic. Thus, we may have less 367 opportunities to view improvement in liver outcomes. 368 369 This study has a number of limitations to be considered. First, the alcohol intake categories variable was created based on the TLFB method to calculate average number of drinks per week. 370 371 A recall bias and social desirability bias in self-reported longitudinal number of drinks per day 372 may lead to an inaccurate estimation of parameter estimates of the model. This may be especially

true during the CM period, as contingencies were aligned with drinking abstinence. Second,

although our results will contribute future understanding on changes in liver outcome measures,

the fitted model was constructed using a dataset with a limited number of covariates and

376 relatively small sample size.

377

Future studies with a larger sample size and diverse cohort characteristics (*e.g.* adjusted
FibroScan scores by GGT and lifestyle variable such as health satisfaction or well-being) are
warranted to validate our findings.

381

382 Acknowledgments

We are grateful for the administrative support of Dr. Christine Frank and for the data
management support of Dr. Zhi Zhou and Mr. Alex Li at the Southern HIV and Alcohol
Research Consortium.

386

387 **References**

388 [1] O'Keefe JH, Bhatti SK, Bajwa A, DiNicolantonio JJ, Lavie CJ. Alcohol and cardiovascular

health: the dose makes the poison...or the remedy. Mayo Clin Proc. 2014;89(3):382-93. doi:

390 10.1016/j.mayocp.2013.11.005. PMID: 24582196.

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

- 391 [2] National Institute on Alcohol Abuse and Alcoholism (NIAAA). 2020. Alcohol and American
- 392 Society: A Complex Relationship. [accessed 2023 February 27].
- 393 <u>https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-impact-</u>
- 394 <u>health</u>.
- 395 [3] Rehm J, Shield KD. Global alcohol-attributable deaths from cancer, liver cirrhosis, and injury
- in 2010. Alcohol Res. 2013;35(2):174-83. PMID: 24881325.
- 397 [4] Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic Liver Disease: Pathogenesis and
- 398 Current Management. Alcohol Res. 2017;38(2):147-161. PMID: 28988570.
- 399 [5] Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: A current molecular and clinical
- 400 perspective. Liver Res. 2018;2(4):161-172. doi: 10.1016/j.livres.2018.11.002. PMID: 31214376.
- 401 [6] Traversy G, Chaput JP. Alcohol Consumption and Obesity: An Update. Curr Obes Rep.
- 402 2015;4(1):122-30. doi: 10.1007/s13679-014-0129-4. PMID: 25741455.
- 403 [7] Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets.
- 404 Gastroenterology. 2011;141(5):1572-85. doi: 10.1053/j.gastro.2011.09.002. PMID: 21920463.
- 405 [8] Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for
- 406 advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol.
- 407 2017;9(2):91-98. doi: 10.4254/wjh.v9.i2.91. PMID: 28144390.
- 408 [9] Barve S, Kapoor R, Moghe A, Ramirez JA, Eaton JW, Gobejishvili L, Joshi-Barve S,
- 409 McClain CJ. Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver
- 410 disease in HIV-infected patients. Alcohol Res Health. 2010;33(3):229-36. PMID: 23584064.
- 411 [10] Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease:
- 412 An update. Hepatology. 2015;62(6):1871-82. doi: 10.1002/hep.28150. PMID: 26340591.
- 413 [11] Nanditha NGA, Paiero A, Tafessu HM, St-Jean M, McLinden T, Justice AC, Kopec J,
- 414 Montaner JSG, Hogg RS, Lima VD. Excess burden of age-associated comorbidities among
- 415 people living with HIV in British Columbia, Canada: a population-based cohort study. BMJ
- 416 Open. 2021;11(1):e041734. doi: 10.1136/bmjopen-2020-041734. PMID: 33419911.
- 417 [12] Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors
- 418 of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017;31(11):1621-1632. doi:
- 419 10.1097/QAD.00000000001504. PMID: 28398960.
- 420 [13] Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient
- 421 Care STDS. 2005;19(6):356-65. doi: 10.1089/apc.2005.19.356. PMID: 15989431.

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

- 422 [14] Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. BMJ
- 423 Open Gastroenterol. 2017;4(1):e000166. doi: 10.1136/bmjgast-2017-000166. PMID: 29119002.
- 424 [15] Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol Use and Human
- 425 Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future
- 426 Directions. Alcohol Clin Exp Res. 2016;40(10):2056-2072. doi: 10.1111/acer.13204. PMID:
- 427 27696523.
- 428 [16] Dougherty DM, Hill-Kapturczak N, Liang Y, Karns TE, Cates SE, Lake SL, Mullen J,
- 429 Roache JD. Use of continuous transdermal alcohol monitoring during a contingency
- 430 management procedure to reduce excessive alcohol use. Drug Alcohol Depend. 2014;142:301-
- 431 306. doi: 10.1016/j.drugalcdep.2014.06.039. PMID: 25064019.
- 432 [17] Barnett NP, Celio MA, Tidey JW, Murphy JG, Colby SM, Swift RM. A preliminary
- 433 randomized controlled trial of contingency management for alcohol use reduction using a
- 434 transdermal alcohol sensor. Addiction. 2017;112(6):1025-1035. doi: 10.1111/add.13767. PMID:
- 435 28107772.
- 436 [18] Mehta G, Macdonald S, Cronberg A, Rosselli M, Khera-Butler T, Sumpter C, Al-Khatib S,
- 437 Jain A, Maurice J, Charalambous C, Gander A, Ju C, Hakan T, Sherwood R, Nair D, Jalan R,
- 438 Moore KP. Short-term abstinence from alcohol and changes in cardiovascular risk factors, liver
- 439 function tests and cancer-related growth factors: a prospective observational study. BMJ Open.
- 440 2018;8(5):e020673. doi: 10.1136/bmjopen-2017-020673. PMID: 29730627.
- 441 [19] Munsterman ID, Groefsema MM, Weijers G, Klein WM, Swinkels DW, Drenth JPH,
- 442 Schellekens AFA, Tjwa ETTL. Biochemical Effects on the Liver of 1 Month of Alcohol
- 443 Abstinence in Moderate Alcohol Consumers. Alcohol Alcohol. 2018;53(4):435-438. doi:
- 444 10.1093/alcalc/agy031. PMID: 29726886.
- 445 [20] Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M,
- 446 Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical
- 447 Investigators. Development of a simple noninvasive index to predict significant fibrosis in
- 448 patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25. doi: 10.1002/hep.21178.
- 449 PMID: 16729309.
- 450 [21] Witkiewitz K, Kranzler HR, Hallgren KA, O'Malley SS, Falk DE, Litten RZ, Hasin DS,
- 451 Mann KF, Anton RF. Drinking Risk Level Reductions Associated with Improvements in

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

- 452 Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcohol Clin
- 453 Exp Res. 2018;42(12):2453-2465. doi: 10.1111/acer.13897. PMID: 30395350.
- 454 [22] Henssler J, Müller M, Carreira H, Bschor T, Heinz A, Baethge C. Controlled drinking-non-
- 455 abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-
- 456 analysis and meta-regression. Addiction. 2021;116(8):1973-1987. doi: 10.1111/add.15329.
- 457 PMID: 33188563.
- 458 [23] Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline
- 459 Followback when administered by telephone and by computer. Drug Alcohol Depend.
- 460 1996;42(1):49-54. doi: 10.1016/0376-8716(96)01263-x. PMID: 8889403.
- 461 [24] National Institute on Alcohol Abuse and Alcoholism (NIAAA). 2021. Rethinking drinking:
- 462 Alcohol and your health. [accessed 2023 February 10].
- 463 <u>https://www.niaaa.nih.gov/sites/default/files/publications/NIAAA_RethinkingDrinking.pdf</u>
- 464 [25] Silverstein PS, Kumar S, Kumar A. HIV-1, HCV and alcohol in the CNS: potential
- 465 interactions and effects on neuroinflammation. Curr HIV Res. 2014;12(4):282-92. doi:
- 466 10.2174/1570162x12666140721122956. PMID: 25053363.
- 467 [26] National Heart, Lung, and Blood Institute (NHLBI). 2013. Managing overweight and
- 468 obesity in Adults: systematic evidence review from the obesity expert panel. [accessed 2023
- 469 February 8]. <u>https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-</u>
- 470 <u>review.pdf</u>.
- 471 [27] Loomis AK, Kabadi S, Preiss D, Hyde C, Bonato V, St Louis M, Desai J, Gill JM, Welsh P,
- 472 Waterworth D, Sattar N. Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two
- 473 Electronic Health Record Prospective Studies. J Clin Endocrinol Metab. 2016;101(3):945-52.
- 474 doi: 10.1210/jc.2015-3444. PMID: 26672639.
- 475 [28] Scheiner B, Steininger L, Semmler G, Unger LW, Schwabl P, Bucsics T, Paternostro R,
- 476 Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Controlled attenuation parameter does not
- 477 predict hepatic decompensation in patients with advanced chronic liver disease. Liver Int.
- 478 2019;39(1):127-135. doi: 10.1111/liv.13943.PMID: 30107095.
- 479 [29] Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in
- 480 Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(5):1264-1281.e4.
- 481 doi: 10.1053/j.gastro.2018.12.036. PMID: 30660725.

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

- 482 [30] Sansom SE, Martin J, Adeyemi O, Burke K, Winston C, Markham S, Go B, Huhn G.
- 483 Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation
- 484 Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency
- 485 Virus/HCV Coinfection in a Large US Hepatitis Clinic. Open Forum Infect Dis.
- 486 2019;6(4):ofz099. doi: 10.1093/ofid/ofz099. PMID: 30968054.
- 487 [31] Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK,
- 488 Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L,
- 489 Small EJ, Morris MJ, Pierce JP, Marshall J. Effect of a Behavioral Intervention to Increase
- 490 Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer:
- 491 The MEAL Randomized Clinical Trial. JAMA. 2020 Jan 14;323(2):140-148. doi:
- 492 10.1001/jama.2019.20207. PMID: 31935026; PMCID: PMC6990696.
- 493 [32] McCambridge J, Jenkins RJ. Do brief interventions which target alcohol consumption also
- 494 reduce cigarette smoking? Systematic review and meta-analysis. Drug Alcohol Depend. 2008
- 495 Aug 1;96(3):263-70. doi: 10.1016/j.drugalcdep.2008.03.011. Epub 2008 May 23. PMID:

496 18457926.

497

498 **Supporting Information**

499 S1 Table. Crude descriptive statistics of liver outcome measures at baseline, 30-days, and
500 90-days.

501

502 S2 Table. Descriptive statistics of change in liver outcome measures at 30-days and 90-days

503 with quit/reduced and continued heavy drinking.

504

505 S3 Table. Changes in liver outcomes associated with changes in alcohol consumption at 30

506 and 90 days among 46 adults participating in a contingency management study.

507

- 508 S4 Table. Changes in liver outcomes associated with changes in alcohol consumption at 30
- 509 and 90 days among 9 adults with abnormal baseline TE (TE \geq 7) participating in a

510 contingency management study.

511

IMPACT OF CONTINGENCY MANAGEMENT ON LIVER ABNORMALITIES

- 512 S5 Table. Changes in liver outcomes associated with changes in alcohol consumption at 30
- 513 and 90 days among 21 adults with abnormal baseline CAP (CAP \geq 238) participating in a
- 514 contingency management study.

